About Sherlock Biosciences
Sherlock Biosciences is a company based in Watertown (United States) founded in 2019 by David Walt, Omar Abudayyeh, and Jonathan Gootenberg was acquired by OraSure in December 2024. It operates as a HealthTech. Sherlock Biosciences has raised $111 million across 8 funding rounds from investors including United States Department of Agriculture, Gates Foundation and OraSure Technologies. The company has 33 employees as of December 31, 2020. Sherlock Biosciences has completed 1 acquisition, including Sense Biodetection. Sherlock Biosciences offers products and services including SHERLOCK™ and INSPECTR™. Sherlock Biosciences operates in a competitive market with competitors including GRAIL, Amyris, Syngenta, AskBio and Color, among others.
- Headquarter Watertown, United States
- Employees 33 as on 31 Dec, 2020
- Founders David Walt, Omar Abudayyeh, Jonathan Gootenberg
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Orasure Technologies, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$111 M (USD)
in 8 rounds
-
Latest Funding Round
$298.95 K (USD), Grant
Aug 08, 2024
-
Investors
United States Department of Agriculture
& 10 more
-
Employee Count
33
as on Dec 31, 2020
- Investments & Acquisitions
-
Acquired by
OraSure
(Dec 19, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sherlock Biosciences
Sherlock Biosciences offers a comprehensive portfolio of products and services, including SHERLOCK™ and INSPECTR™.
CRISPR-based tool for rapid DNA/RNA detection used.
Synthetic biology platform for affordable diagnostics developed.
People of Sherlock Biosciences
Unlock access to complete
Leadership Team
8 people
Product Management Team
4 people
Finance and Accounting
2 people
Legal and Compliance
1 people
Human Resources and Administration
1 people
Operations Team
1 people
Chair Team
1 people
Software Development Team
1 people
Unlock access to complete
Funding Insights of Sherlock Biosciences
Sherlock Biosciences has successfully raised a total of $111M across 8 strategic funding rounds. The most recent funding activity was a Grant round of $298.95 thousand completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sherlock Biosciences
Sherlock Biosciences has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include United States Department of Agriculture, Gates Foundation and OraSure Technologies.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment and advisory services are provided for life sciences.
|
Locked | Locked | Locked | |
|
Health tech startups are invested in by Illumina Ventures.
|
Locked | Locked | Locked | |
|
Investments in healthtech startups are made by Albany Capital.
|
Locked | Locked | Locked |
Investor details for Sherlock Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sherlock Biosciences
Sherlock Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Sense Biodetection.
Investment portfolio details for Sherlock Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of point of care molecular diagnostics solutions
|
Locked | Locked | 2014 | Locked |
Complete acquisition details for Sherlock Biosciences
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Sherlock Biosciences
Detailed financials for Sherlock Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sherlock Biosciences Comparisons
Peer comparison for Sherlock Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sherlock Biosciences
Sherlock Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GRAIL, Amyris, Syngenta, AskBio and Color, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Developer of renewable products for industrial solutions
|
|
| Locked | Locked | Locked |
Crop protection solutions and hybrid seeds are provided for farming.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Cancer care is delivered through a virtual clinic by Color.
|
|
| Locked | Locked | Locked |
Gene editing-based cultured ingredients are provided for agriculture.
|
Detailed competitors of Sherlock Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sherlock Biosciences
Complete news archive for Sherlock Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sherlock Biosciences
Sherlock Biosciences was founded in 2019.
Sherlock Biosciences is headquartered in Watertown, United States.
Bryan Dechairo is the current CEO of Sherlock Biosciences.
Sherlock Biosciences is a funded company, having raised a total of $111M across 8 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Sherlock Biosciences is 33.
Sherlock Biosciences, a subsidiary of OraSure Technologies, is dedicated to the development of molecular diagnostics using CRISPR and synthetic biology. The company is engaged in creating rapid, accurate, and affordable diagnostic tools through proprietary platforms like SHERLOCK and INSPECTR. Solutions are designed for point-of-need testing to democratize and decentralize healthcare. The focus is on personalizing healthcare and impacting global health by enabling accessible diagnostic answers in various settings.
Sherlock Biosciences offers SHERLOCK™ and INSPECTR™.
Sherlock Biosciences has made 1 acquisition, including Sense Biodetection.
Sherlock Biosciences has 11 investors. Key investors include United States Department of Agriculture, Gates Foundation, OraSure Technologies, Novalis LifeSciences, and Illumina Ventures.